+

WO2002009815A3 - Nouvelle composition pharmaceutique - Google Patents

Nouvelle composition pharmaceutique Download PDF

Info

Publication number
WO2002009815A3
WO2002009815A3 PCT/EP2001/008363 EP0108363W WO0209815A3 WO 2002009815 A3 WO2002009815 A3 WO 2002009815A3 EP 0108363 W EP0108363 W EP 0108363W WO 0209815 A3 WO0209815 A3 WO 0209815A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
new pharmaceutical
relates
composition
compositions
Prior art date
Application number
PCT/EP2001/008363
Other languages
English (en)
Other versions
WO2002009815A2 (fr
Inventor
Pierre Barbier
Paul Hadvary
Hans Lengsfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002009815(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020037001277A priority Critical patent/KR100572785B1/ko
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to BRPI0112799A priority patent/BR0112799B1/pt
Priority to JP2002515366A priority patent/JP4265911B2/ja
Priority to PL366105A priority patent/PL204443B1/pl
Priority to AU2001289699A priority patent/AU2001289699B2/en
Priority to CA002416901A priority patent/CA2416901C/fr
Priority to PT01969439T priority patent/PT1307264E/pt
Priority to MXPA03000771A priority patent/MXPA03000771A/es
Priority to HU0301281A priority patent/HU229292B1/hu
Priority to IL15400801A priority patent/IL154008A0/xx
Priority to DK01969439T priority patent/DK1307264T3/da
Priority to NZ523684A priority patent/NZ523684A/en
Priority to SI200130249T priority patent/SI1307264T1/xx
Priority to DE60106623T priority patent/DE60106623T2/de
Priority to AU8969901A priority patent/AU8969901A/xx
Priority to AT01969439T priority patent/ATE279961T1/de
Priority to MEP-905/08A priority patent/MEP90508A/xx
Priority to EP01969439A priority patent/EP1307264B1/fr
Publication of WO2002009815A2 publication Critical patent/WO2002009815A2/fr
Publication of WO2002009815A3 publication Critical patent/WO2002009815A3/fr
Priority to IL154008A priority patent/IL154008A/en
Priority to HR20030029A priority patent/HRP20030029B1/xx
Priority to NO20030418A priority patent/NO330546B1/no
Priority to HK04101443A priority patent/HK1058636A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des combinaisons pharmaceutiques, des compositions et des traitements de l'obésité. L'invention se réfère plus particulièrement trait à une combinaison ou à une composition contenant un inhibiteur de lipase, de préférence un orlistat et un agent séquestrant d'acides biliaires.
PCT/EP2001/008363 2000-07-28 2001-07-19 Nouvelle composition pharmaceutique WO2002009815A2 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SI200130249T SI1307264T1 (en) 2000-07-28 2001-07-19 New pharmaceutical composition
NZ523684A NZ523684A (en) 2000-07-28 2001-07-19 New pharmaceutical composition
BRPI0112799A BR0112799B1 (pt) 2000-07-28 2001-07-19 Pharmaceutical composition, process for the preparation of the same, use of a lipase inhibitor and a bilic acid sequestrant
JP2002515366A JP4265911B2 (ja) 2000-07-28 2001-07-19 新規医薬組成物
PL366105A PL204443B1 (pl) 2000-07-28 2001-07-19 Kompozycja farmaceutyczna zawierająca inhibitor lipazy, sposób wytwarzania kompozycji farmaceutycznej, zestaw do leczenia otyłości, zastosowanie kompozycji farmaceutycznej oraz zastosowanie orlistatu i substancji wiążącej kwasy żółciowe
AU2001289699A AU2001289699B2 (en) 2000-07-28 2001-07-19 New pharmaceutical composition
CA002416901A CA2416901C (fr) 2000-07-28 2001-07-19 Compositions pharmaceutiques comportant un ihibiteur des lipases et un sequestrant d'acide biliaire et leurs utilisations pour la prevention et le traitement de l'obesite
PT01969439T PT1307264E (pt) 2000-07-28 2001-07-19 Nova composicao farmaceutica
MXPA03000771A MXPA03000771A (es) 2000-07-28 2001-07-19 Nuevas composiciones farmaceuticas.
HU0301281A HU229292B1 (en) 2000-07-28 2001-07-19 New pharmaceutical composition
IL15400801A IL154008A0 (en) 2000-07-28 2001-07-19 New pharmaceutical composition
KR1020037001277A KR100572785B1 (ko) 2000-07-28 2001-07-19 신규한 약학 조성물
DE60106623T DE60106623T2 (de) 2000-07-28 2001-07-19 Neue pharmazeutische zusammensetzung
DK01969439T DK1307264T3 (da) 2001-07-19 2001-07-19 Hidtil ukendt farmaceutisk præparat
EP01969439A EP1307264B1 (fr) 2000-07-28 2001-07-19 Nouvelle composition pharmaceutique
AU8969901A AU8969901A (en) 2000-07-28 2001-07-19 New pharmaceutical composition
AT01969439T ATE279961T1 (de) 2000-07-28 2001-07-19 Neue pharmazeutische zusammensetzung
MEP-905/08A MEP90508A (en) 2000-07-28 2001-07-19 New pharmaceutical composition
IL154008A IL154008A (en) 2000-07-28 2003-01-16 Pharmaceutical preparations containing orlistat as a lipase inhibitor, processes for their production, kits containing them and their use in the preparation of drugs for the treatment and prevention of obesity
HR20030029A HRP20030029B1 (en) 2000-07-28 2003-01-17 New pharmaceutical composition
NO20030418A NO330546B1 (no) 2000-07-28 2003-01-27 Farmasoytisk preparat omfattende orlistat, sett omfattende slike, fremgangsmate for fremstilling av slike samt anvendelse som slike for behandling og forebygging av fedme.
HK04101443A HK1058636A1 (en) 2000-07-28 2004-02-27 New pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00116393.0 2000-07-28
EP00116393 2000-07-28

Publications (2)

Publication Number Publication Date
WO2002009815A2 WO2002009815A2 (fr) 2002-02-07
WO2002009815A3 true WO2002009815A3 (fr) 2002-04-18

Family

ID=8169384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008363 WO2002009815A2 (fr) 2000-07-28 2001-07-19 Nouvelle composition pharmaceutique

Country Status (38)

Country Link
US (5) US6756364B2 (fr)
EP (1) EP1307264B1 (fr)
JP (2) JP4265911B2 (fr)
KR (1) KR100572785B1 (fr)
CN (1) CN100423715C (fr)
AR (1) AR033548A1 (fr)
AT (1) ATE279961T1 (fr)
AU (2) AU8969901A (fr)
BR (1) BR0112799B1 (fr)
CA (1) CA2416901C (fr)
CZ (1) CZ302087B6 (fr)
DE (1) DE60106623T2 (fr)
EC (1) ECSP034450A (fr)
EG (1) EG24357A (fr)
ES (1) ES2230362T3 (fr)
GT (1) GT200100152A (fr)
HK (1) HK1058636A1 (fr)
HR (1) HRP20030029B1 (fr)
HU (1) HU229292B1 (fr)
IL (2) IL154008A0 (fr)
JO (1) JO2320B1 (fr)
MA (1) MA26937A1 (fr)
ME (1) MEP90508A (fr)
MX (1) MXPA03000771A (fr)
MY (1) MY127247A (fr)
NO (1) NO330546B1 (fr)
NZ (1) NZ523684A (fr)
PA (1) PA8523201A1 (fr)
PE (1) PE20020336A1 (fr)
PL (1) PL204443B1 (fr)
PT (1) PT1307264E (fr)
RS (1) RS50397B (fr)
RU (1) RU2241462C2 (fr)
SI (1) SI1307264T1 (fr)
TW (1) TWI275395B (fr)
UY (1) UY26860A1 (fr)
WO (1) WO2002009815A2 (fr)
ZA (1) ZA200300456B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2775800C2 (ru) * 2016-02-09 2022-07-11 Альбирео Аб Пеллеты колестирамина и способы их получения
US11844822B2 (en) 2014-06-25 2023-12-19 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154008A0 (en) * 2000-07-28 2003-07-31 Hoffmann La Roche New pharmaceutical composition
EP1307263B1 (fr) * 2000-07-28 2005-04-20 F. Hoffmann-La Roche Ag Nouvelle application d'inhibiteurs de lipase
US7033373B2 (en) 2000-11-03 2006-04-25 Satiety, Inc. Method and device for use in minimally invasive placement of space-occupying intragastric devices
US6558400B2 (en) 2001-05-30 2003-05-06 Satiety, Inc. Obesity treatment tools and methods
US7083629B2 (en) 2001-05-30 2006-08-01 Satiety, Inc. Overtube apparatus for insertion into a body
MXPA04010371A (es) * 2002-04-26 2005-02-03 Hoffmann La Roche Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan.
US6746460B2 (en) 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
US7214233B2 (en) 2002-08-30 2007-05-08 Satiety, Inc. Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
US7033384B2 (en) 2002-08-30 2006-04-25 Satiety, Inc. Stented anchoring of gastric space-occupying devices
JP2006508916A (ja) * 2002-09-09 2006-03-16 ネーデルランドセ・オルガニザテイエ・フール・テゲパスト−ナトウールベテンシヤツペリーク・オンデルツエク・テイエヌオー 体重管理のための分枝アルファ−グルカン
US7229428B2 (en) 2002-10-23 2007-06-12 Satiety, Inc. Method and device for use in endoscopic organ procedures
US7220237B2 (en) 2002-10-23 2007-05-22 Satiety, Inc. Method and device for use in endoscopic organ procedures
US6656194B1 (en) 2002-11-05 2003-12-02 Satiety, Inc. Magnetic anchoring devices
CA2521379C (fr) 2003-04-08 2013-07-02 Progenics Pharmaceuticals, Inc. Formulations pharmaceutiques contenant de la methylnaltrexone
US7175638B2 (en) 2003-04-16 2007-02-13 Satiety, Inc. Method and devices for modifying the function of a body organ
US7097650B2 (en) * 2003-10-14 2006-08-29 Satiety, Inc. System for tissue approximation and fixation
US7914543B2 (en) 2003-10-14 2011-03-29 Satiety, Inc. Single fold device for tissue fixation
US8070937B2 (en) * 2003-12-19 2011-12-06 Shell Oil Company Systems, methods, and catalysts for producing a crude product
US20050177176A1 (en) 2004-02-05 2005-08-11 Craig Gerbi Single-fold system for tissue approximation and fixation
WO2005079673A2 (fr) 2004-02-13 2005-09-01 Satiety, Inc. Methode de reduction du volume d'un organe creux
WO2006004574A2 (fr) * 2004-02-19 2006-01-12 Abbott Laboratories Methode d'utilisation de gamma cyclodextrine dans la regulation de la glycemie et de la secretion d'insuline
CA2557722C (fr) 2004-02-27 2013-02-12 Satiety, Inc. Procedes et dispositifs pour reduire le volume d'organes creux
US8449560B2 (en) 2004-03-09 2013-05-28 Satiety, Inc. Devices and methods for placement of partitions within a hollow body organ
US8628547B2 (en) 2004-03-09 2014-01-14 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8252009B2 (en) 2004-03-09 2012-08-28 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US9028511B2 (en) 2004-03-09 2015-05-12 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US7753870B2 (en) 2004-03-26 2010-07-13 Satiety, Inc. Systems and methods for treating obesity
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
WO2006035296A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Procede de preparation d'un derive d'orlistat utile comme standard de reference dans la determination de la purete d'orlistat et procede de preparation d'orlistat
US20060106288A1 (en) 2004-11-17 2006-05-18 Roth Alex T Remote tissue retraction device
JP5241484B2 (ja) * 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20090208584A1 (en) * 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
WO2006134591A2 (fr) * 2005-06-13 2006-12-21 Yeda Research And Development Co. Ltd. Utilisation d'allylmercaptocaptopril pour traiter ou prevenir l'obesite et des maladies associees a l'obesite
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
US20090162314A1 (en) * 2005-11-08 2009-06-25 Huval Chad C Magnesium-Containing Polymers for the Treatment of Hyperphosphatemia
WO2007070801A2 (fr) * 2005-12-12 2007-06-21 Allaccem, Inc. Procedes et systemes de preparation de films et de revetements antimicrobiens
EP1803714A1 (fr) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Procédé de préparation de formes cristallines de orlistat
EP1984328A2 (fr) * 2006-01-25 2008-10-29 Yeda Research And Development Co., Ltd. Procede de preparation d allylmercaptocaptopril (cpssa) et de disulfures asymetriques correspondants
US7749536B2 (en) * 2006-02-14 2010-07-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
PL1818048T3 (pl) * 2006-02-14 2009-06-30 Teva Pharma Formulacje farmaceutyczne zawierające polimery amin alifatycznych oraz sposoby ich wytwarzania
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
CA2749074A1 (fr) 2006-09-01 2008-05-29 Usv Limited Procede de preparation d'hydrochlorure de sevelamer et formulation de celui-ci
US20080069906A1 (en) * 2006-09-18 2008-03-20 Thompson Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
US7662373B2 (en) * 2006-09-18 2010-02-16 Thompson Ronald J Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
WO2008070308A2 (fr) * 2006-10-24 2008-06-12 Thompson Md Ronald J Procédé et composition d'une herbe carminative ou d'un complément naturel permettant de diminuer les effets néfastes de l'orlistat, un inhibiteur de lipase oral, et un procédé avec des formulations permettant simultanément de réduire un risque de fracture et d'assurer
EP2478895A3 (fr) * 2006-12-22 2012-12-19 Ironwood Pharmaceuticals, Inc. Compositions permettant de traiter des troubles oesophagiens
EP1944025A1 (fr) * 2007-01-09 2008-07-16 Ranbaxy Laboratories Limited Compositions pharmaceutiques stables d'orlistat
ES2522908T3 (es) 2007-02-21 2014-11-19 Allaccem, Inc. Composiciones a base de compuestos policíclicos con puente para la inhibición y el alivio de enfermedades
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
AR065877A1 (es) 2007-03-29 2009-07-08 Progenics Pharm Inc Antagonoistas del receptor opioide periferico y usos de los mismos
ES2765811T5 (es) 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
EP2730578A1 (fr) 2008-02-06 2014-05-14 Progenics Pharmaceuticals, Inc. Préparation et utilisation de (r),(r)-2,2'-bis-methylnal trexone
PL216542B1 (pl) * 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
EP2278966B1 (fr) 2008-03-21 2019-10-09 The University of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
CA2735962A1 (fr) * 2008-09-02 2010-04-15 Usv Limited Polymeres reticules
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
JP2012509891A (ja) 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
WO2010093243A1 (fr) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Utilisation d'une combinaison de diazoxyde et de metformine pour le traitement de l'obésité ou des troubles liés à l'obésité
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
US20110152204A1 (en) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of Obesity or Diabetes with Bile Acid Sequestrants
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
SG10201406155QA (en) 2011-10-28 2014-11-27 Lumena Pharmaceuticals Inc Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
SG11201401849QA (en) 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2591768B1 (fr) * 2011-11-14 2014-07-16 Deva Holding Anonim Sirketi Formulations de dose unitaire de sevelamer et des vitamines liposolubles et des tensioactifs
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
SI2916852T1 (sl) 2012-11-06 2021-08-31 Sigrid Therapeutics Ab Porozni silicijev dioksid za uporabo kot farmacevtska ali prehranska aktivna učinkovina
TWI614017B (zh) 2012-12-21 2018-02-11 財團法人國家衛生研究院 包含中孔洞矽奈米粒子之組成物的用途
RU2552926C1 (ru) * 2014-06-23 2015-06-10 Общество с ограниченной ответственностью "ПРОМОМЕД" Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
EP3012252A1 (fr) 2014-10-24 2016-04-27 Ferring BV Formes crystallines d'Elobixibat
EP3413875B1 (fr) * 2016-02-09 2020-01-29 Albireo AB Pastilles de cholestyramine et procédés de préparation associés
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
EP3664781A1 (fr) * 2017-08-09 2020-06-17 Albireo AB Granules de cholestyramine, formulations orales de cholestyramine et leur utilisation
US11389545B2 (en) * 2018-01-09 2022-07-19 Aqua Regenerative Therapies Llc Bioactive nanoparticles and methods for making same
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CR20210026A (es) 2018-06-20 2021-03-18 Albireo Ab Modificaciones de cristales de odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
CN108685848B (zh) * 2018-08-13 2020-09-01 中山万汉制药有限公司 一种奥利司他口服乳剂及其制备方法
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN111297826B (zh) * 2020-04-20 2021-08-03 鲁南制药集团股份有限公司 一种稳定的奥利司他胶囊及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643874A (en) * 1993-08-05 1997-07-01 Hoffmann-La Roche Inc. Pharmaceutical composition comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
CA1247547A (fr) 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
DE3414609C1 (de) * 1984-04-18 1985-06-20 Daimler-Benz Ag, 7000 Stuttgart Vorrichtung zur Beeinflussung eines Kuehlluftstromes
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5063210A (en) 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5344453A (en) * 1991-05-30 1994-09-06 Boston Medical Products, Inc. Thyroplasty implant
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JP3832871B2 (ja) * 1995-04-03 2006-10-11 日本製粉株式会社 リパーゼ阻害剤
WO1997023210A1 (fr) 1995-12-26 1997-07-03 Suntory Limited Agent anti-obesite dont le principe actif est la procyanidine
US5612026A (en) * 1996-01-25 1997-03-18 The Procter & Gamble Company Cholesterol lowering drink mix compositons
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
JP3807464B2 (ja) 1997-11-17 2006-08-09 康二 嘉島 肥満防止剤
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
RU2222335C2 (ru) 1998-01-09 2004-01-27 Джензайм Корпорейшн Жиросвязывающие полимеры
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
FI113356B (fi) 1998-05-20 2004-04-15 Upm Kymmene Corp Pakkauksenmuodostuslaite
EP1105123B1 (fr) * 1998-08-14 2004-04-07 F.Hoffmann-La Roche Ag Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane
BR9912980B1 (pt) * 1998-08-14 2013-10-22 Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma
EP1112063A4 (fr) 1998-09-08 2009-05-13 Smithkline Beecham Corp Comprimes a base de fibres solubles et d'un derive de lipstatine
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
KR20010101594A (ko) 1999-01-22 2001-11-14 훈자 디 마리아 카르멜라 마라찌타 에스.아.에스. 지단백질 복합체 및 이를 함유하는 조성물
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
IL154008A0 (en) * 2000-07-28 2003-07-31 Hoffmann La Roche New pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643874A (en) * 1993-08-05 1997-07-01 Hoffmann-La Roche Inc. Pharmaceutical composition comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844822B2 (en) 2014-06-25 2023-12-19 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
RU2775800C2 (ru) * 2016-02-09 2022-07-11 Альбирео Аб Пеллеты колестирамина и способы их получения

Also Published As

Publication number Publication date
MXPA03000771A (es) 2003-06-04
US20060269510A1 (en) 2006-11-30
YU5003A (sh) 2006-01-16
PT1307264E (pt) 2005-02-28
AU8969901A (en) 2002-02-13
HRP20030029B1 (en) 2005-06-30
EP1307264A2 (fr) 2003-05-07
JO2320B1 (en) 2005-09-12
CZ2003582A3 (cs) 2004-02-18
GT200100152A (es) 2002-05-16
KR100572785B1 (ko) 2006-04-19
CN1444495A (zh) 2003-09-24
US6756364B2 (en) 2004-06-29
JP4265911B2 (ja) 2009-05-20
US20050136030A1 (en) 2005-06-23
IL154008A (en) 2011-12-29
JP2009073833A (ja) 2009-04-09
HU229292B1 (en) 2013-10-28
NO20030418L (no) 2003-01-27
CA2416901C (fr) 2007-07-03
KR20030029796A (ko) 2003-04-16
NO20030418D0 (no) 2003-01-27
US20040105838A1 (en) 2004-06-03
US20100203032A1 (en) 2010-08-12
ATE279961T1 (de) 2004-11-15
RS50397B (sr) 2009-12-31
IL154008A0 (en) 2003-07-31
MA26937A1 (fr) 2004-12-20
AR033548A1 (es) 2003-12-26
CA2416901A1 (fr) 2002-02-07
HUP0301281A2 (hu) 2003-08-28
SI1307264T1 (en) 2005-02-28
CN100423715C (zh) 2008-10-08
ZA200300456B (en) 2004-04-16
AU2001289699B2 (en) 2006-06-01
DE60106623T2 (de) 2006-02-02
PA8523201A1 (es) 2002-10-24
PL204443B1 (pl) 2010-01-29
PE20020336A1 (es) 2002-05-08
EG24357A (en) 2009-03-04
US8071571B2 (en) 2011-12-06
ME00671B (fr) 2011-12-20
CZ302087B6 (cs) 2010-10-06
ECSP034450A (es) 2003-03-10
JP2004505067A (ja) 2004-02-19
PL366105A1 (en) 2005-01-24
HUP0301281A3 (en) 2005-05-30
BR0112799A (pt) 2003-07-01
DE60106623D1 (de) 2004-11-25
HK1058636A1 (en) 2004-05-28
WO2002009815A2 (fr) 2002-02-07
BR0112799B1 (pt) 2017-10-24
HRP20030029A2 (en) 2004-02-29
US20020035089A1 (en) 2002-03-21
MEP90508A (en) 2011-12-20
NO330546B1 (no) 2011-05-16
NZ523684A (en) 2005-04-29
MY127247A (en) 2006-11-30
ES2230362T3 (es) 2005-05-01
TWI275395B (en) 2007-03-11
UY26860A1 (es) 2002-01-31
EP1307264B1 (fr) 2004-10-20
RU2241462C2 (ru) 2004-12-10

Similar Documents

Publication Publication Date Title
WO2002009815A3 (fr) Nouvelle composition pharmaceutique
WO2001062280A3 (fr) Composition contenant une lipase et ses procedes d'utilisation
WO2003059296A3 (fr) Compositions a base de collagene et procedes d'utilisation
AU2002300709A1 (en) Corrosion inhibiting compositions
CA2416900A1 (fr) L'utilisation combine d'un inhibiteur des lipases et d'un sequestrant d'acide biliaire pharmaceutiquement acceptable pour le traitement des maladies associees avec les niveaux eleves de cholesterol dans le plasma
WO2001079461A3 (fr) Polypeptides a activite haloperoxydase
AU2001232377A1 (en) The method of advertisement using online games
MXPA03005275A (es) Prevencion de la captacion de conservantes en biomateriales.
WO2000077206A3 (fr) Promoteur du gene de la myostatine et methode pouvant inhiber l'activation dudit promoteur
WO2003047558A3 (fr) Traitement de troubles du systeme nerveux central a l'aide d'inhibiteurs de d-amino-oxydase et de d-aspartate oxydase
EP1183011A4 (fr) Methode, compositions pharmaceutiques et trousse de traitement de l'angine et/ou d'equivalents angineux
WO2002009757A1 (fr) Agents de prevention ou remedes contre l'obesite ou la steatose hepatique
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU2001247947A1 (en) Composition for treating steel making slags
WO2004026892A3 (fr) Fragmentation d'adn
AU2001294062A1 (en) Method of treating aqueous compositions
WO2001070953A3 (fr) Traitement de la restenose
WO2002016338A8 (fr) Aminoalkenylbenzoyl-benzofuranes ou benzothiophenes, leur procede de preparation et les compositions les contenant
WO2001036515A3 (fr) Compositions polymeriques et leur procede de preparation
WO2004112843A3 (fr) Compositions et procedes de controle des odeurs
WO2003031584A3 (fr) Reparation d'axone
AU2002360343A1 (en) Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
WO2000017133A3 (fr) Inhibiteurs de lta4 hydrolase
MXPA03006468A (es) Composiciones para la prevencion o tratamiento de hepatopatia.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-50/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2003/00456

Country of ref document: ZA

Ref document number: 154008

Country of ref document: IL

Ref document number: 200300456

Country of ref document: ZA

Ref document number: 523684

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: P20030029A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2001969439

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2416901

Country of ref document: CA

Ref document number: 03003685A

Country of ref document: CO

Ref document number: 03003685

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 136/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 03004385

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/000771

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 018135196

Country of ref document: CN

Ref document number: 1020037001277

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001289699

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2003-582

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2003104801

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 1020037001277

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001969439

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-582

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2001969439

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 523684

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523684

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 1020037001277

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载